Table 1 Cohort clinical characteristics measured per line of mCRPC therapya
Patient characteristic | First line (n = 463) | Second line (n = 213) | Third line (n = 62) |
|---|---|---|---|
Age at initial prostate cancer diagnosis (years) | 68 (41–96) | 67 (41–86) | 63 (41–75) |
Gleason Grade Group 4–5 | 71% (245) | 71% (96) | 71% (32) |
De novo metastatic diagnosis | 46% (171) | 49% (69) | 42% (19) |
Treatment intensification for mCSPC | 17% (81) | 11% (25) | 13% (8) |
Taxane chemotherapy (docetaxel) | 16% (74) | 11% (25) | 12% (7) |
Abiraterone, enzalutamide | 2% (6) | 0% (0) | 0% (0) |
Other | <1% (1) | 0% (0) | 0% (0) |
CRPC within 12 months of ADT initiation | 40% (174) | 53% (104) | 57% (32) |
Age at systemic mCRPC treatment initiation (years) | 73 (45–98) | 73 (45–93) | 69 (45–88) |
Systemic treatment for mCRPC | 100% (463) | 100% (213) | 100% (62) |
Taxane chemotherapy (docetaxel or cabazitaxel) | 8% (39) | 17% (37) | 49% (30) |
Abiraterone, enzalutamide | 91% (420) | 78% (166) | 11% (7) |
Other | 1% (4) | 5% (10) | 40% (25) |
ECOG performance status 0–1 | 86% (345) | 70% (143) | 70% (37) |
Alkaline phosphatase > ULN | 35% (155) | 34% (73) | 45% (27) |
Lactate dehydrogenase > ULN | 23% (93) | 22% (45) | 36% (19) |
Hemoglobin (g/L) | 130 (79–174) | 128 (79–157) | 127 (97–156) |
PSA (ng/mL, plasma) | 26 (0–5800) | 19 (0.2–1604) | 53 (3.8–812) |
Visceral metastases | 18% (83) | 24% (51) | 29% (18) |
Lymph-node only metastases | 12% (55) | 7% (15) | 10% (8) |
Cell-free DNA concentration (ng/ml) | 14 (1.5–3870) | 15 (2.4–1650) | 16 (1.1–2140) |
ctDNA fraction | 5% (0–89) | 5% (0–89) | 10% (0–77) |
ctDNA concentration (ng/mL) | 0.7 (0–3146) | 0.5 (0–771) | 1.14 (0–1286) |
ctDNA not detected (i.e., <2%) | 38% (174) | 39% (83) | 18% (11) |
ctDNA fraction 2–30% | 40% (187) | 42% (90) | 53% (33) |
ctDNA fraction >30% | 22% (102) | 19% (40) | 29% (18) |
Follow-up for OS (months) | 20 (0.36–81.6) | 14 (0.52–63.5) | 11 (2.16–32.8) |
Median OS (months)b | 25 (22.4–28.2) | 15.7 (13.6–17.8) | 11.1 (8.7–14.4) |
